Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE) (a registered branch of the ESC).
Rosa Sicari, Petros Nihoyannopoulos, Arturo Evangelista...
https://pubmed.ncbi.nlm.nih.gov/18579481/Actively Recruiting
Led by Quovadis Associazione · Updated on 2025-07-29
120
Participants Needed
13
Research Sites
N/A
Total Duration
Researchers are evaluating the long-term clinical and instrumental response to Cardiac Contractility Modulation CCM therapy in adults with symptomatic heart failure caused by systolic left ventricular dysfunction despite adequate medical treatment. This observational cohort study, both retrospective and prospective, focuses on subjects already receiving CCM as part of their regular care. The study aims to assess clinical response, hospitalizations, quality of life, walking distance, and changes in heart biomarkers over 12 months. Participants carry the OPTIMIZER Smart Mini CCM device, a programmable implantable pulse generator connected to leads in the heart. The study groups are defined by their response to low-dose dobutamine stress echocardiography before implantation, with one group showing a reduction of 15% or more in left ventricular end-systolic volume LVESV and the other less than 15%. The low-dose dobutamine test involves incremental infusions of the drug to assess heart contractile reserve. During the 12-month follow-up, researchers will monitor changes in New York Heart Association NYHA class, hospitalizations, quality of life using the Minnesota Living with Heart Failure Questionnaire, walking test distance, and NT-proBNP biomarker levels. Additional assessments include echocardiographic measures and recording adverse events, cardiac device implants, or surgery. This comprehensive monitoring helps evaluate the clinical and functional effects of CCM therapy over time.
CONDITIONS
The Predictive Value of Dobutamine Echo-stress in the Clinical Response to CCM Therapy in Advanced HF
F
Franco Noventa, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Quovadis Associazione
Lead Sponsor
Impulse Dynamics
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants receive the Cardiac Contractility Modulation (CCM) device implant to support heart function despite optimal medical therapy.
1 implantation visit (in-person)
Duration - 12 months
Participants are monitored for clinical response and heart function improvement after CCM implantation, including assessments with low-dose dobutamine stress echocardiography.
Regular visits during follow-up for up to 12 months
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Rosa Sicari, Petros Nihoyannopoulos, Arturo Evangelista...
https://pubmed.ncbi.nlm.nih.gov/18579481/William T Abraham, Karl-Heinz Kuck, Rochelle L Goldsmith...
https://pubmed.ncbi.nlm.nih.gov/29754812/Maria Lucia Narducci, Mario Cesare Nurchis, Federico Ballacci...
https://pubmed.ncbi.nlm.nih.gov/37943287/Klaus Witte, Gerd Hasenfuss, Axel Kloppe...
https://pubmed.ncbi.nlm.nih.gov/31997539/Patricia A Pellikka, Sherif F Nagueh, Abdou A Elhendy...
https://pubmed.ncbi.nlm.nih.gov/17765820/Martin Borggrefe, Daniel Burkhoff
https://pubmed.ncbi.nlm.nih.gov/22696514/Gianluigi Savarese, Peter Moritz Becher, Lars H Lund...
https://pubmed.ncbi.nlm.nih.gov/35150240/H Nägele, S Behrens, C Eisermann
https://pubmed.ncbi.nlm.nih.gov/18776196/Alan Kadish, Koonlawee Nademanee, Kent Volosin...
https://pubmed.ncbi.nlm.nih.gov/21315216/Wilfried Mullens, Jeroen Dauw, Finn Gustafsson...
https://pubmed.ncbi.nlm.nih.gov/38269474/Quovadis Associazione
Lead Sponsor
Impulse Dynamics
Collaborating Sponsor